[{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Modafinil","moa":"Dopamine transporter||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Modafinil","moa":"Dopamine transporter||GM-CSF","graph1":"Oncology","graph2":"Phase I","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Modafinil","moa":"Dopamine transporter||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Modafinil","moa":"Dopamine transporter||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Modafinil","moa":"Dopamine transporter||GM-CSF","graph1":"Oncology","graph2":"Phase III","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Modafinil","moa":"Dopamine transporter||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Modafinil","moa":"Dopamine transporter||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Modafinil","moa":"Dopamine transporter||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gradalis \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Genentech"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Modafinil","moa":"Dopamine transporter||GM-CSF","graph1":"Oncology","graph2":"Undisclosed","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"pbi-shRNA EWS\/FLI1 Type 1 Lipoplex","moa":"EWS\/FLI1 fusion protein","graph1":"Oncology","graph2":"Phase I","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Funding","leadProduct":"Gemogenovatucel-T","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Gradalis \/ CPRIT","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ CPRIT"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Gemogenovatucel-T","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2012","type":"Inapplicable","leadProduct":"pbi-shRNA STMN1","moa":"STMN1 messenger RNA (STMN1 mRNA)","graph1":"Oncology","graph2":"Phase I","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GRAD1405","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"Vigil Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"Vigil Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2013","type":"Inapplicable","leadProduct":"Vigil Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Undisclosed"},{"orgOrder":0,"company":"Gradalis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"Vigil Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Gradalis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gradalis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gradalis \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Gradalis
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
